LEO Pharma udpeger Rhonda Duffy som leder af Global Product Supply
Rhonda Duffy har stor erfaring med supply chain management i medicinalindustrien, og hun kender LEO Pharma rigtig godt," siger Gitte P. Aabo, administrerende direktør for LEO Pharma. "Vi hjælper i dag mere end 80 millioner patienter verden over, lancerer flere produkter og har en ambitiøs pipeline. En effektiv global supply chain er derfor afgørende for vores succes. Rhonda Duffy er den helt rigtige person til at fortsætte vores arbejde med at optimere og fremtidssikre vores produktion."
Duffy kom til LEO Pharma i 1993 og har siden da været ansvarlig for centrale dele af Global Product Supply. Hun har i sin seneste rolle været Vice President for Dermatology Value Stream, med ansvar for produktionsanlæg i Danmark, Irland og Australien. Hun har formået at optimere og gennemføre turn-arounds af flere produktionssteder, der under hendes lederskab er blev væsentligt mere effektive. Duffy har en ph.d.-grad i farmakognosi fra Pharmacy School, Trinity College, Dublin, Ireland.
Rhonda Duffy overtager rollen som Senior Vice President efter Jim McPherson, som med succes har ledet LEO Pharmas Global Product Supply de seneste tre år.
Kontakter
Maia Søchting
Global External Communications
E-mail: MFDDK@leo-pharma.com
Mobile: +45 3119 3559
Billeder
Information om LEO Pharma
Om LEO Pharma
LEO Pharma hjælper mennesker til at få en sund hud. Ved at tilbyde løsninger til patienter i mere end 100 lande på verdensplan hjælper LEO Pharma mennesker til at håndtere deres hudlidelser. Grundlagt i 1908 og ejet af LEO Fondet har lægemiddelvirksomheden dedikeret årtiers forskning og udvikling til at levere produkter og løsninger til mennesker med hudlidelser. LEO Pharma har hovedkvarter i Danmark og har ca. 5.200 ansatte over hele verden.
For mere information, se www.leo-pharma.com
LinkedIn: www.linkedin.com/company/leo-pharma
YouTube: www.youtube.com/leopharmaglobal
Følg pressemeddelelser fra LEO Pharma
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra LEO Pharma
Annual report 2023: LEO Pharma delivers 10% revenue growth and returns to positive EBITDA29.2.2024 14:00:00 CET | Pressemeddelelse
Ballerup, February 29, 2024. – LEO Pharma delivers a solid operational performance uplift with double-digit revenue growth and an EBITDA uplift of DKK 2.1 billion, corresponding to a 20%-points margin improvement. LEO Pharma exceeded our profitability guidance and hit the upper range of our revenue growth guidance provided in March 2023.
LEO Pharma announces positive phase 3 head-to-head data results from DELTA FORCE trial comparing delgocitinib cream with alitretinoin capsules in adults with severe chronic hand eczema (CHE)24.1.2024 08:00:00 CET | Pressemeddelelse
Delgocitinib cream demonstrated a superior reduction in Hand Eczema Severity Index (HECSI) score from baseline to Week 12 compared to alitretinoin capsules as its primary outcome measure. Delgocitinib cream also demonstrated superiority to alitretinoin capsules in all key secondary outcome measures, including Investigator’s Global Assessment (IGA)-CHE treatment success, health-related quality of life (HRQoL), and a lower number of treatment-emergent adverse events. DELTA FORCE is the first head-to-head phase 3 trial comparing a systemic and topical treatment for CHE.1 With only one treatment option currently approved for severe CHE and no approved optionsfor more moderate forms of the disease, there is a considerable unmet need for patients living with CHE.
LEO Pharma finalizes acquisition of key assets from Timber Pharmaceuticals23.1.2024 12:30:00 CET | Pressemeddelelse
Strategic acquisition to expand pipeline, accelerate growth, and meet unmet needs in medical dermatology.
LEO Pharma announces positive outcome of DELTA 3 open-label extension trial of delgocitinib cream in the treatment of adults with moderate to severe chronic hand eczema (CHE)30.10.2023 10:00:00 CET | Pressemeddelelse
Subjects who completed the 16-week twice-daily treatment regimen of delgocitinib cream or cream vehicle in the phase 3 DELTA 1 or DELTA 2 trials were offered to immediately enroll into the 36-week DELTA 3 extension trial.1 The DELTA 3 trial evaluated the long-term safety of twice-daily as needed treatment with delgocitinib cream for up to 36 weeks in adults with moderate to severe CHE.1 The long-term safety profile of delgocitinib cream was consistent with previous results from the DELTA 1 and 2 trials. Patients who entered the DELTA 3 trial after receiving delgocitinib cream in the DELTA 1 and DELTA 2 trials maintained similar levels of symptom relief and treatment success over an additional 36-week treatment regimen.
LEO Pharma provides update on the development program for izuforant20.10.2023 09:43:02 CEST | Pressemeddelelse
The Phase 2a/b international trial to evaluate the efficacy and safety of orally administered izuforant tablets compared with placebo tablets for up to 16 weeks of treatment in adults with moderate to severe AD did not meet the primary endpoint. As a result, LEO Pharma ends the program for izuforant and terminates the license agreement with JW Pharmaceutical. LEO Pharma remains committed to delivering value for patients living with atopic dermatitis and other skin diseases.
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum